School of Medicine


Showing 1-7 of 7 Results

  • Jason Merker

    Jason Merker

    Assistant Professor of Pathology at the Stanford University Medical Center

    Bio Dr. Merker is co-director of the Stanford Medicine Clinical Genomics Service, a joint effort between Stanford Children’s Health, Stanford Health Care, and the Stanford School of Medicine. The Clinical Genomics Service is clinical and laboratory service that uses genome sequencing and other advanced molecular testing to assist in the diagnosis of genetic disease. Dr. Merker received his M.D. and Ph.D. in Genetics from the University of North Carolina at Chapel Hill. He then completed residency training in Clinical Pathology and fellowship training in Molecular Genetic Pathology and Clinical Cytogenetics at Stanford Hospital and Clinics, followed post-doctoral training in cancer genomics at Stanford University. Dr. Merker also directs a research group that focuses on two areas. First, the laboratory uses classical genetics, genomics, and functional studies to identify and characterize acquired and heritable genetic variants important for the development of hematologic disorders and other malignancies. Second, the laboratory evaluates the clinical utility of genomic and other omics-based approaches for translation into clinical care.

  • Sara Michie

    Sara Michie

    Professor of Pathology

    Current Research and Scholarly Interests Lymphocyte/endothelial cell adhesion mechanisms involved in lymphocyte migration to sites of inflammation; regulation of expression of endothelial cell adhesion molecules.

  • Stephen B. Montgomery

    Stephen B. Montgomery

    Assistant Professor of Pathology, Genetics and, by courtesy, of Computer Science

    Current Research and Scholarly Interests We focus on understanding the effects of genome variation on cellular phenotypes and cellular modeling of disease through genomic approaches such as next generation RNA sequencing in combination with developing and utilizing state-of-the-art bioinformatics and statistical genetics approaches. See our website at http://montgomerylab.stanford.edu/

  • Thomas Montine

    Thomas Montine

    Professor of Pathology

    Bio Dr. Montine received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Nancy and Buster Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington, and in 2012 he became Director of the University of Washington Alzheimer’s Disease Research Center. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford Unviversity.

    Dr. Montine is the founding Director of the Pacific Northwest Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson’s Disease Research. Our center performs basic, translational, and clinical research focused on cognitive impairment in Parkinson’s disease. The Pacific Northwest Udall Center emphasizes a vision for precision health that comprises functional genomics, development of surveillance tools for pre-clinical detection, and discovery of molecularly tailored therapies.

    Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States. He was the 2015 President of the American Association of Neuropathologists, and led or co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer’s disease (NIA), develop research priorities for the National Alzheimer’s Plan (NINDS & NIA), and develop research priorities for Parkinson’s Disease (NINDS).

    The focus of the Montine Laboratory is on the structural and molecular bases of cognitive impairment. Our goal is to define key pathogenic steps and thereby identify new therapeutic targets. The Montine Laboratory addresses these prevalent, unmet medical needs through a combination of neuropathology, biomarker development and application early in the course of disease, and experimental studies that test hypotheses concerning specific mechanisms of neuron injury and approaches to neuroprotection. PubMed lists 511 publications for Dr. Montine. In May 2016, Google Scholar calculates Dr. Montine’s citations as > 25,500 and his H-Index as 83.